growing, yet little is known about the variation in procedural outcomes in community practice. We developed a TAVR inhospital mortality risk model and used it to quantify variation in mortality rates across United States (US) TAVR centers. Methods and Results-We analyzed data from 22 248 TAVR procedures performed at 318 sites participating in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry (November 2011 to October 2014). A Bayesian hierarchical model was developed to estimate hospital-specific risk-adjusted mortality rates adjusting for 40 patient baseline factors. A total of 1130 in-hospital deaths (5.1%) were observed. Reliability-adjusted risk-adjusted mortality rate estimates ranged from 3.4% to 7.7% with an interquartile range of 4.8% to 5.4%. A patient's predicted odds of dying was 80% higher if treated by a hospital 1 standard deviation above the mean compared with a hospital 1 standard deviation below the mean (odds ratio =1.8; 95% credible interval, 1.4%-2.2%). Conclusions-Risk modeling of TAVR in-hospital mortality revealed variation in risk-adjusted mortality rates during the US early commercial experience. Transcatheter Valve Therapy Registry analyses using this model will support research, feedback reporting, and the identification of factors associated with quality. (Circ Cardiovasc Qual Outcomes. 2016;9:560-565.
A fter regulatory approval by the United States Food and Drug Administration in 2011, transcatheter aortic valve replacement (TAVR) has been used with increasing frequency to treat patients with severe aortic stenosis who are at high risk of mortality or morbidity with conventional surgical aortic valve replacement. 1, 2 As a result, the use of TAVR has expanded rapidly throughout the United States to centers with varying degrees of experience using TAVR. Recent studies from the Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) Transcatheter Valve Therapy (TVT) Registry have documented 30-day and 1-year TAVR outcomes in the United States, 1, 3 but the extent to which these outcomes vary across hospitals has not been reported.
Editorial, see p 498
For many procedures performed by interventional cardiologists and cardiac surgeons, risk-adjusted outcome metrics have been developed, applied, and validated using large clinical registries, such as the STS Adult Cardiac Surgery Database and the ACC National Cardiovascular Data Registry. For example, models to assess institutional performance have been developed for coronary artery bypass grafting, 4 valve surgery, 5 and percutaneous coronary intervention. 6, 7 Recent studies have developed parsimonious prediction models to facilitate patient selection and counseling for TAVR. [8] [9] [10] However, a TAVR risk model customized for institutional performance assessment was not previously available.
This study was conducted using data from the STS/ACC TVT Registry. Our specific goals were to (1) develop a TAVR in-hospital mortality risk model suitable for research and feedback reporting in the TVT Registry and (2) characterize variation in mortality across centers during the US early commercial experience.
Methods

The STS/ACC TVT Registry
The STS/ACC TVT Registry was created in 2011 to monitor patient safety and real-world outcomes of emerging treatments for valve disease. The registry's major goals are to monitor outcomes of transcatheter valve procedures in real-world patients, assess the learning curve among centers beginning to adopt the technology, and provide a ready-made infrastructure for research and safety surveillance. As a condition for Medicare coverage, all US TAVR hospitals are required to collect data on consecutively enrolled patients receiving a Food and Drug Administration-approved transcatheter heart valve. Centers participating in the TVT Registry receive quarterly reports comparing each center's case mix, practice patterns, and outcomes to the national experience. Performance measures developed within the TVT Registry are intended to promote quality improvement, identify characteristics of high-performing centers, and inform the design of interventions to improve patient outcomes.
Cohort Selection
We included all TVT records for patients undergoing TAVR with a commercially approved device between November 1, 2011, and October 31, 2014. From a starting population of 22 271 TAVR cases, we excluded 23 cases (0.1%) with missing data for discharge mortality status. TAVR procedures aborted intraoperatively were included in this cohort in keeping with the analysis principle of intention to treat.
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End Point
We used in-hospital rather than 30-day mortality status as the primary outcome measure because in-hospital mortality status was reported in 99.9% of records, whereas 30-day mortality status was missing in 20% at the time of model development initiation.
Descriptive Analyses
Patient baseline characteristics were summarized for the overall cohort, as well as for each individual center, to assess variation in case mix across hospitals. Baseline summaries included percentages and median values as appropriate. For describing center-specific unadjusted mortality rates, each center's unadjusted (observed) discharge mortality rate was calculated and plotted in relation to the center's number of eligible cases (ie, the center's sample size). Lines depicting exact 95% binomial prediction limits were overlaid to show the expected range of sampling variation that would normally occur under the hypothesis of no true center-level variation in mortality.
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Covariates for Case-Mix Adjustment
Details of the covariate selection process are described in the Methods in the Data Supplement. Briefly, our multivariable analysis was designed to estimate center-specific mortality rates after adjusting for patient baseline factors and to determine the amount of variation in these rates that is because of true hospital-level differences (ie, signal) as opposed to random error (ie, noise). Accordingly, covariates for multivariable analysis were selected with the goal of minimizing potential confounding by case mix and without regard for the model's parsimony (Table I in the Data Supplement). A total of 40 baseline factors were selected. The main considerations for covariate selection included clinical relevance, variation across hospitals, and data quality. Frailty, as assessed by the 5-m walk assessment, and cardiovascular-specific functional status, as assessed by the Kansas City Cardiomyopathy Questionnaire, are known to be prognostically significant, 14, 15 but were missing too frequently (60% and 61%, respectively) to be included in the model. Remaining model covariates were highly complete, with most covariates having <1% missing data and only one covariate having >3% missing data (number of prior cardiac operations; missing 3.6%). In the rare case of missing data, unknown values were imputed to the most common category of categorical variables and to the median or subgroup-specific median of continuous variables. More computationally intensive missing data strategies, such as multiple imputation, were not used for this analysis because of the low rate of missing data and because it would be impractical to implement them in combination with the computationally intensive Markov Chain Monte Carlo estimation procedure described below.
Multivariable Analysis
For modeling procedural acuity, a categorical variable was created by combining the procedure status field with 4 relatively rare highrisk preprocedure conditions: (1) cardiac arrest within 24 hours; (2) cardiac shock within 24 hours; (3) inotropes; and (4) mechanical assist device. Patients with none of these high-risk conditions were assigned to category 1 if status was elective or category 2 if status was urgent. Remaining patients were assigned to category 3 if status was elective or urgent and there was no cardiac arrest within 24 hours or category 4, otherwise.
To estimate center-specific mortality rates, we fit a hierarchical logistic regression model with adjustment for 40 prespecified patient baseline factors and center-specific random intercepts (Table II in the Data Supplement). Before making inferences about hospital performance, the model's fit to the data was assessed internally. Calibration was assessed by comparing observed versus expected mortality rates overall and within subgroups, based on deciles of predicted risk. Discrimination was assessed by the C statistic. After confirming satisfactory internal calibration and discrimination, the model was
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• Since its approval by the United States (US) Food and Drug Administration in 2011, transcatheter aortic valve replacement (TAVR) has been used with increasing frequency to treat patients with severe aortic stenosis who are at high risk of mortality and morbidity with conventional surgical aortic valve replacement. • A risk model customized for TAVR institutional performance assessment was not previously available.
WHAT THIS STUDY ADDS
• Risk modeling of TAVR in-hospital mortality revealed variation in risk-adjusted mortality rates during the early US commercial experience.
• Transcatheter Valve Therapy Registry analyses using this model will support research, feedback reporting, and the identification of factors associated with quality.
re-estimated using a 70% random sample of records and assessed for calibration and discrimination in the remaining 30% of records. A center's standardized mortality ratio was defined as the ratio of the center's true mortality rate according to the model divided by the mortality rate that would be expected for a hypothetical center with the same case mix and an intercept parameter equal to the population average (see Methods in the Data Supplement for details). A hospital's risk-adjusted mortality rate (RAMR) was defined by the formula RAMR=(standardized mortality ratio)×(overall mortality rate), where "overall mortality rate" denotes the observed discharge mortality rate among all patients in the overall study cohort. Definitions of the variables used in the multivariable analysis can be found in Table  III in the Data Supplement.
Estimation
Model parameters were estimated in a Bayesian statistical framework by specifying a prior probability distribution for unknown parameters and using Markov Chain Monte Carlo simulations for inference. Briefly, Bayesian inference uses the language of probability to express beliefs about clinically interesting hypotheses and quantities. The output of a Bayesian analysis is a probability distribution describing the most likely numeric estimates of unknown model parameters. Markov Chain Monte Carlo simulations are used to generate representative samples of parameter values, which are then analyzed to create appropriate estimates and summary measures. Advantages of fully Bayesian estimation include the ability to perform inference about complex functions of unknown quantities (eg, the variance of RAMRs across hospitals) and the ability to calculate the probability of any clinically interesting hypothesis (eg, the probability that a given center's RAMR is greater than the national average). Unlike frequentist confidence intervals, Bayesian interval estimates (known as credible intervals [CrIs] ) have an intuitively direct interpretation as an interval containing the true value with a specified probability (eg, 95%).
Bayesian estimators of hospital-specific mortality incorporate a reliability adjustment (also known as shrinkage) that diminishes the apparent variation in mortality rates across hospitals. [16] [17] [18] Although such estimators are optimal for the purpose of estimating each hospital's unknown mortality rate, 19 the distribution of reliability-adjusted mortality rates may severely underestimate the true amount of signal variation. [20] [21] [22] Therefore, to appropriately characterize the magnitude of true signal variation, the following approach was adopted. First, using the model's estimated variance parameter, we 
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Results
Study Cohort
The final study population included 22 248 index TAVR procedures from 318 US hospitals with a median of 58 (interquartile range [IQR] 22-96) eligible cases per hospital. The median age was 84 years, and 50% were female. Patient characteristics varied substantially across hospitals. Even after excluding hospitals with <100 cases, there was more than a 5-fold difference across hospitals for the majority of baseline factors examined (Table) . For example, the proportion of patients with a prior aortic procedure varied >100-fold, ranging from 0.6% to 70.2% across hospitals. New York Heart Association Class IV heart failure varied 29-fold, ranging from 3.3% to 96.9% across hospitals. Among centers with at least 100 cases and at least 30 cases with nonmissing 5-m walk assessment, the proportion of patients requiring >10 seconds to walk 5 m varied from 6% to 81% across centers.
Unadjusted Mortality
There were a total of 1130 in-hospital deaths during the study period (5.1%). Hospital-specific observed mortality rates ranged from 0% to 33.3% (IQR 2.4%-7.1%). For the vast majority of centers (96%), the observed mortality rate fell within the expected range of normal sampling variation (Figure 1 ).
Multivariable Analysis
The multivariable association between each model covariate and in-hospital mortality based on the final model is summarized in Table II in the Data Supplement. Binary factors with the largest estimated ORs included dialysis (OR=2.4), nonfemoral access (OR=1.9), and severe chronic lung disease (OR=1.5). As expected, mortality risk was highest in the highest category of procedural acuity (OR=3.7).
Calibration plots demonstrated high agreement between observed and expected mortality rates, both overall and within prespecified subgroups (Figures I and II in the Data Supplement). The C statistic was 0.71 in the overall sample and 0.67 in the 30% cross-validation sample (Table IV in the  Data Supplement) .
A patient's predicted odds of dying was 80% higher if treated by a hospital 1 standard deviation above the mean compared with 1 standard deviation below the mean (OR=1.8; 95% CrI, 1.4%-2.2%). Figure 2 summarizes the estimated distribution of hospital-specific true RAMRs in the form of a histogram. The estimated IQR was 4.3% to 6.1%. The estimated average RAMR ranged from 3.2% to 8.1% among hospitals in the lowest and highest mortality deciles, respectively (risk difference=5.0% [95% CrI, 3.0%-6.9%]; risk ratio=2.6 [95% CrI, 1.8%-3.5%]).
Reliability-adjusted estimates of individual hospitalspecific RAMRs ranged from 3.4% to 7.7% with an IQR of 4.8% to 5.4%. Only one hospital had an RAMR statistically distinguishable from the TVT average ( Figure 3 ). As noted in the Methods section, the variation in these reliability-adjusted estimates is a downwardly biased estimate of the true variation in RAMRs across hospitals. As a result, the IQR reported here is slightly narrower than the correctly estimated IQR of true RAMRs, as reported in Figure 2 .
Discussion
In this report of the US early commercial experience with TAVR, we found significant hospital-level variation in riskadjusted TAVR mortality rates among US hospitals. These findings support the hypothesis that institutional factors may play a role in affecting patient outcomes. As TAVR continues to evolve, risk models developed in the TAVR population will support research, feedback reporting, and the identification of factors associated with quality.
Nevertheless, our results also demonstrate the challenges in outcomes performance evaluation at this early stage in the procedure's adoption curve. Given the low number of cases performed at many sites, measured mortality rates are expected to vary substantially by chance alone. Consequently, despite evidence of true signal variation, only one hospital had an RAMR statistically distinguishable from the TVT average. Estimating the amount of residual variation not caused by chance required a relatively complex statistical strategy.
Overall, the early message of the US TAVR experience is positive. Our current findings indicate that many community sites are achieving procedural outcomes similar to or better Overall mortality rate, 5.1% 95% probability interval Figure 1 . Hospital-specific observed mortality rates. Funnel plot of hospital-specific observed mortality rates with 95% prediction limits.
than those seen in the pivotal clinical trial experience. However, there is evidence of site-to-site variation both in the types of patients treated and in adjusted acute outcomes. Understanding what site characteristics and processes may be associated with excellent or poor outcomes will be an important direction for future quality improvement and research efforts. The STS and ACC have long recognized and emphasized the importance of continual assessment of TAVR outcomes, but outcomes analysis has been limited by the lack of a customized TAVR risk-adjustment methodology. 25 To adjust for case mix in this study, we used hierarchical logistic regression and included all baseline factors with a known or suspected association with mortality as covariates. Before estimating center-level performance, the model was empirically tested to evaluate internal calibration and to assess the impact of various methodological decisions. For estimation, we used a fully Bayesian approach that permits making intuitively appealing probability statements about each hospital's performance. The Bayesian method also appropriately accounts for overfitting by allowing uncertainty in the estimation of regression coefficients to be appropriately reflected in wider confidence intervals. To further enhance validity, the models used in this project were developed by a panel of statistical and clinical experts and were circulated for public comment on the ACC's mailing list and website. Public comments were carefully considered in the approach to model development.
The risk adjustment techniques used in this study were developed not only for quantifying variation across TAVR hospitals, but also for use in a variety of future planned quality improvement and research efforts. Based on this article's risk-adjustment method, centers in the TVT Registry will receive quarterly feedback reports comparing their RAMR to the national experience. Additional performance measures for nonfatal end points (eg, stroke and bleeding) are planned for development and will provide complementary information for a more comprehensive assessment of TAVR outcomes. Oneyear outcomes are also being tracked in the TVT Registry 3 and will be the focus of future risk modeling efforts.
Limitations
This study has several limitations. First, although the model adjusted for a large number of patient factors, several known or suspected risk factors were not included. Variables such as 5-m walk assessment and baseline functional status are known to be prognostically significant for mortality after TAVR, 14, 15 but were missing in >50% of records in this early stage of national data collection. In centers performing the 5-m walk assessment, the distribution of walk times was highly variable across centers, suggesting a potential for bias from differential case mix. To the extent that frailty is correlated with other variables in the risk-adjustment model, the potential for bias is lessened. Second, although our analysis documented significant variation in mortality, it did not identify specific factors explaining this variation. The effects of provider experience and volume on mortality were not analyzed in the current study, but will be an important topic for future study. Third, we analyzed a single-end point discharge mortality and did not analyze long-term mortality or nonfatal end points. The development of TAVR-specific risk models for these other end points is a high STS and ACC priority. Fourth, generalizability is impacted by the exclusion of noncommercial cases and the availability of only one Food and Drug Administration-approved device during the majority of the study period. Finally, for reasons related to statistical power and sample size, we were unable to determine whether between-center variation in mortality has increased or decreased over the study period.
Conclusions
Risk adjustment of TAVR in-hospital mortality revealed center-level variation during the US early commercial experience. TVT Registry analyses using this model will support research, feedback reporting, and the identification of factors associated with quality. Participant Sorted by Estimated RAMR Risk−Adjusted Mortality Rate (%) Figure 3 . Hospital-specific risk-adjusted mortality rates (RAMR) estimates. Hospital-specific RAMR estimates with 95% Bayesian credible intervals. RAMR indicates risk-adjusted mortality rate.
